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Abstract 
Background: Randomised controlled trials provide high-level evidence, but the necessity to 
include selected patients may limit the generalisability of their results.  
Methods: Comparisons were made of baseline and outcome data between patients with acute 
ischaemic stroke (AIS) recruited into the alteplase-dose arm of the international, multi-centre, 
Enhanced Control of Hypertension and Thrombolysis Stroke study (ENCHANTED) in the 
United Kingdom (UK), and alteplase-treated AIS patients registered in the UK Sentinel 
Stroke National Audit Programme (SSNAP) registry, over the study period June 2012 to 
October 2015. 
Results:  There were 770 AIS patients (41.2% female; mean age 72 years) included in 
ENCHANTED at sites in England and Wales, which was 19.5% of alteplase-treated AIS 
patients registered in the SSNAP registry.  Trial participants were significantly older, had 
lower baseline neurological severity, less likely Asian, and had more premorbid symptoms, 
hypertension and atrial fibrillation.  Although ENCHANTED participants had higher rates of 
symptomatic intracerebral haemorrhage than those in SSNAP, there were no differences in 
onset-to-treatment time, levels of disability (assessed by the modified Rankin scale) at 
hospital discharge, and mortality over 90 days between groups. 
Conclusions:  Despite the high level of participation, equipoise over the dose of alteplase 
among UK clinician investigators favoured the inclusion of older, frailer, milder AIS patients 
in the ENCHANTED trial.   
Clinical Trial Registration: Clinical Trial Registration-URL: http://www.clinicaltrials.gov. 
Unique identifier: NCT01422616 
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Introduction 
Reperfusion therapy with intravenous (iv) alteplase (or recombinant tissue plasminogen 
activator) is approved for the treatment of time-selected patients with acute ischaemic stroke 
(AIS) [1], but controversy exists over the most safe and efficacious dose.  Concerns over the 
risk of symptomatic intracerebral haemorrhage (sICH), the most serious complication of iv 
alteplase, and its affordability in low resource settings, has led to lower doses being used in 
many Asian AIS patients [2] after a dose of 0.6 mg/kg was approved in Japan.  The Enhanced 
Control of Hypertension and Thrombolysis Stroke study (ENCHANTED) provided the first 
randomised evaluation of the effectiveness of low-dose (0.6mg/kg body weight) compared to 
standard-dose (0.9mg/kg) iv alteplase in thrombolysis-eligible AIS patients [3].  Although the 
study was unable to demonstrate non-inferiority between the doses on the primary endpoint of 
death or disability (modified Rankin scale [mRS] scores 2-6) at 90 days, it clearly showed a 
reduced risk of sICH with the lower dose of alteplase.  The results were translated into the 
recent United Kingdom (UK) National Clinical Guidelines for stroke as showing: “a lower 
risk of ICH and early mortality with the lower dose, without conclusively demonstrating that 
the doses were of equivalent efficacy, such that there may be circumstances in which the 
treating physician and/or patient wish to forgo some of the potential disability benefit from 
standard dose in order to reduce the early risk of ICH through use of the lower dose” [4].  Yet, 
despite being a pragmatic study with broad eligibility criteria, concerns have been expressed 
about the generalisability of the ENCHANTED results as, like all clinical trials, it involved 
selected participants [5].  We wished to assess the degree of selection bias in ENCHANTED 
by comparing the characteristics and outcomes of AIS patient participants with other 
alteplase-treated AIS patients at participating sites in England and Wales.  The comparison 
AIS population was derived from the UK Sentinel Stroke National Audit Programme 
(SSNAP), a prospective, national, continuous stroke register of patients (age >16 years) in 
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England and Wales, which captures over 90% of all hospital stroke admissions in these 
countries [6].   
Methods 
Design 
The ENCHANTED trial is an international, multi-centre, prospective, randomised, open-
label, blinded-endpoint trial with a 2x2 partial-factorial design to assess the effectiveness of 
low- versus standard-dose alteplase (the completed arm), and more intensive- versus 
guideline-recommended control of blood pressure (BP) (the ongoing arm); full details of 
which are outlined elsewhere [3,7].  These analyses consider the 770 AIS patients who were 
treated at participating sites in England and Wales between 18 June 2012 and 14 October 
2015.  Thrombolysis-eligible AIS patients were randomly allocated to treatment with low-
dose (0.6mg/kg; 15% as bolus, 85% as infusion over 1 hour) or standard-dose (0.9mg/kg; 
10% as bolus, 90% as infusion over 1 hour) iv alteplase.  The study protocol was approved by 
the appropriate ethics committee at each participating site, and written informed consent was 
obtained from patients or an appropriate surrogate.  Ethical approval for use of relevant 
SSNAP data was granted by the Ethics and Confidentiality Committee of the National 
Information Governance Board.  Mortality data were obtained through data linkage with the 
statutory register of deaths, undertaken by a third party using an anonymised dataset.   
Procedures 
Key demographic and clinical characteristics of AIS patients were recorded at the time of 
enrollment in ENCHANTED, and within a median of 20 days of hospital admission in 
SSNAP.  Stroke severity was measured with the National Institutes of Health stroke scale 
(NIHSS) at baseline and at 24 hours (in those patients receiving thrombolysis).  The primary 
clinical outcome of ENCHANTED was the combined endpoint of death or disability (mRS 
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scores 2-6) at 90 days.  However, mRS scores at hospital discharge and mortality within 90 
days were used for these analyses as these outcomes were common to both datasets.  The 
safety outcome was sICH, defined according to the National Institute of Neurological 
Disorders and Stroke (NINDS) criteria (i.e. any ICH associated with neurological 
deterioration, >1 point increase in NIHSS scores from baseline or death within 24 to 36 
hours) was also common to both datasets [8].  
Statistical analysis 
Key baseline characteristics and 90-day outcomes are summarised as mean (SD), median 
(interquartile range [IQR]) and percent for normally distributed, skewed, and categorical data, 
respectively.  P values were obtained from the Kruskal-Wallis test for continuous data or chi-
squared for categorical data.  A two-sided P value <0.05 was set as the level for statistical 
significance, and no adjustment was made for multiplicity of testing.  All statistical analyses 
were performed using SAS version 9.3 (SAS institute, Cary, NC, USA). 
Role of the funding source 
The sponsors had no role in the study design, data collection, data analysis, data interpretation 
or writing of the report.  All authors had full access to the study data.  The corresponding 
author had final responsibility for the decision to submit the paper for publication.  
Results 
These analyses involve the 770 AIS patients (41.2% female; mean age 72 years) randomised 
to the alteplase-dose arm of ENCHANTED in England and Wales, which corresponds to 
1.9% of 39,835 hospitalised stroke patients correspondingly entered onto the SSNAP registry 
over respective recruitment time periods at these 30 trial sites.  Of 34,932 AIS patients 
registered in SSNAP, 5,937 were potentially eligible for ENCHANTED according to the 
inclusion and exclusion criteria of the study, and 3,957 did receive thrombolysis treatment.  
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Thus, ENCHANTED included approximately one fifth (19.5%) of all thrombolysis-eligible 
and treated AIS patients in England and Wales. 
Overall, 213,886 stroke patients were registered with SSNAP across 206 sites in England and 
Wales during the study period.  Of these, 187,283 had AIS and 28,800 fulfilled eligibility 
criteria for ENCHANTED, with 18,109 (62.9%) actually receiving thrombolysis treatment. 
Table 1 outlines the key baseline characteristics of the AIS population eligible for 
ENCHANTED at all SSNAP sites in England and Wales.  Compared to AIS patients in the 
SSNAP registry, ENCHANTED participants were older, less often Asian, had lower mean 
baseline NIHSS scores, and more pre-morbid symptoms, hypertension and atrial fibrillation.  
However, no significant differences were evident in median (IQR) times from the onset of 
symptoms to treatment between ENCHANTED participants and potentially eligible AIS 
patients, and between those AIS patients thrombolysed at ENCHANTED sites (137 [107-180] 
minutes) and all SSNAP sites (142 [111-181]).  Other key baseline characteristics and data on 
alteplase use and management over the first seven days among trial participants, as compared 
to the total ENCHANTED population, are provided in Supplementary Tables S1 and S2, 
respectively. 
Table 2 shows comparable 90-day mortality between ENCHANTED participants, and eligible 
and thrombolysis-treated SSNAP patients at ENCHANTED participating sites.  
ENCHANTED participants were significantly less likely to have moderate-to-severe 
disability (mRS score 4: requiring assistance with daily living) at hospital separation as 
compared to ENCHANTED-eligible and thrombolysis-treated SSNAP patients (8.9% vs. 
14.3%; P<0.0001), and they tended to be free of substantial disability (mRS score 1: 23.8 vs. 
20.6%; P=0.054).  There were no other differences in outcomes (Table 2, Figure).  Although 
ENCHANTED participants had significantly higher rates of sICH than ENCHANTED 
eligible and thrombolysis-treated SSNAP patients (5.1 vs. 3.4%; P=0.028), there was no 
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difference in deaths, and neurological deterioration was significantly lower in the former (6.9 
vs. 11.7%; P<0.0001) (Table 3).  
Discussion 
Our study compared participants of the multi-centre ENCHANTED trial that assessed two 
different doses of iv alteplase, with the contemporaneous population of hospitalised AIS 
patients who fulfilled the study eligibility criteria and were thrombolysed at sites in England 
and Wales over the study period.  The use of a pragmatic design with simple criteria and data 
collection requirements resulted in ENCHANTED achieving a high level of recruitment, 
approximately one in five of potentially thrombolysis-eligible AIS patients within the 
research network.  However, these analyses show the trial had a degree of selection bias, 
reflected in differences in the characteristics and outcomes between AIS patients within and 
outside the trial.  Compared to background AIS patients, trial participants were older, had 
greater premorbid health problems, and presented at later times after the onset of symptoms, 
all of which may have contributed to their higher rate of sICH despite presenting with milder 
neurological severity.  These findings are likely to reflect the equipoise of investigators over 
the AIS patients to be included in the trial to address the research question under 
investigation. 
Randomised controlled trials provide the highest level of quality in evaluating interventions, 
but they are limited by a degree of external validity, or generalisability, from selection bias 
associated with the necessity to restrict including patients based on certain inclusion/exclusion 
criteria.  In the era of ‘big data’, disease registries add value in determining ‘real life’ 
efficacy, provision of outcomes on rare diseases, and providing rapid review of the 
application of treatments as data accumulate [9].  As demonstrated in Scandinavia, registries 
can complement clinical trial data to monitor and continuously improve health services and 
patient outcomes [10].  
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With its high level of data acquisition and coverage [6], the SSNAP registry provided an ideal 
opportunity to compare our trial participants with the near whole, hospitalised, AIS 
population in England and Wales.  In general, though, clinical trials tend to include younger 
and healthier ‘diseased’ participants.  For example, in the Improved Reduction of Outcomes: 
Vytorin Efficacy International Trial (IMPROVE-IT) of ezetimibe compared to simvastatin, 
patients with an acute coronary syndrome tended to be younger, healthier and to have had 
more optimal therapies compared to those in the ambulatory cardiology practice-performance 
registry of the American College of Cardiology [11].  It is apparent that due to their concerns 
about the risks of sICH, ENCHANTED investigators narrowed their clinical equipoise over 
the dose of alteplase in favour of older, milder AIS patients, whereas younger AIS patients 
with more severe deficits tended to be excluded from participation and treated with standard-
dose alteplase. 
In the United States, participation in the Get-with-the-Guidelines-Stroke registry of the 
American Heart Association / American Stroke Association has been shown to increase 
adherence to various performance measures related to patient outcomes, independent of 
hospital size, teaching status and geographical location [12].  We were unable to find any 
significant differences between trial and non-trial AIS patients, in relation to the clinical 
outcomes of mortality and disability, but our analyses were limited by the patient and site 
numbers.  Another limitation of our study is that it was a post-hoc analysis within a single 
region, which together with open nature of the trial raises the potential for bias and chance 
associations.  Moreover, the ENCHANTED trial used the primary outcome measure at the 
conventional time point of 90 days post-randomisation, but the mRS was only routinely 
collected at the time of hospital discharge in the SSNAP registry.  Thus, as well as variability 
around the reliability of the mRS outcome measure between studies [13], there may be 
concerns about the utility of discharge mRS score in predicting 90-day outcome [14]. 
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In summary, we have shown significant differences between trial and hospital populations in 
participating English and Welsh centres in the ENCHANTED trial and SSNAP registry, 
respectively.  Importantly, the trial population tended to be older, and have pre-existing co-
morbidities and milder neurological severity, which likely reflect the treating clinician’s 
decision to include them.  However, these factors were associated with a higher rate of sICH, 
although this did not translate into worse mortality or disability compared to the broader AIS 
population.  This study highlights the degree of selection bias underlying clinical trials but 
also the importance of disease registries in monitoring systems of care and health outcomes. 
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Figure legend 
Global functional outcome at 90 days in participants of the ENCHANTED trial and in 
patients with acute ischaemic stroke in the SSNAP register who were eligible and treated with 
intravenous alteplase.  The figure shows the raw distribution of scores on the modified Rankin 
scale (mRS) at 90 days.  Scores on the mRS range from 0 to 6, with 0 indicating no 
symptoms; 1 symptoms without clinical significant disability; 2 slight disability; 3 moderate 
disability; 4 moderately severe disability; 5 severe disability; and 6, death. 
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Table 1.  Selected baseline and management characteristics of ENCHANTED participants compared to eligible and treated patients at 
ENCHANTED and all SSNAP sites in England and Wales 
 SSNAP sites participating in ENCHANTED   All SSNAP sites 
Variable 
Trial participants 
(n=770) 
Eligible patients 
(n=5,937) 
Eligible/treated 
patients 
(n=3,957) 
P value§  Eligible patients  
(n=28,800) 
Eligible/treated 
patients  
(n=18,109) 
Age, years 
  >80  
72 (14) 
252/ 770 (32.7) 
71 (14) 
1751/5937 (29.5) 
70 (14) 
1143/3957 (28.9) 
0.001 
0.032 
 71 (14) 
9018/28800 (31.3) 
71 (14) 
5362/18109 (29.6) 
Female 317/ 770 (41.2) 2573/5937 (43.3) 1716/3957 (43.4) 0.26  12596/28800 (43.7) 7914/18109 (43.7) 
Non-Asian ethnicity 753/ 770 (97.8) 5724/5937 (96.4) 3811/3957 (96.3) 0.039  28033/28800 (97.3) 17617/18109 (97.3) 
NIHSS score,† 7.0 (5.0-13.0) 7.0 (3.0-14.0) 10.0 (6.0-16.0)   7.0 (3.0-13.0) 10.0 (6.0-16.0) 
Onset to treatment, mins 139 (110-177) N/A 137 (107-180)   N/A 142 (111-181) 
Medical history 
  Hypertension 
  Atrial fibrillation* 
  Diabetes 
 Antiplatelet therapy^ 
 Anticoagulation^ 
 
471/ 770 (61.2) 
187/ 768 (24.3) 
134/ 770 (17.4) 
77/187 (41.2) 
14/187 (7.5) 
 
3257/5937 (54.9) 
982/5937 (16.5) 
1049/5937 (17.7) 
413/982 (42.1) 
237/982 (24.1) 
 
2109/3957 (53.3) 
679/3957 (17.2) 
633/3957 (16.0) 
299/679 (44.0) 
125/679 (18.4) 
 
<0.0001 
<0.0001 
0.34 
0.56 
0.0001 
  
15094/28800 (52.4) 
4847/28800 (16.8) 
4752/28800 (16.5) 
2187/4847 (45.1) 
1271/4847 (26.2) 
 
9380/18109 (51.8) 
3135/18109 (17.3) 
2811/18109 (15.5) 
1462/3135 (46.6) 
641/3135 (20.4) 
Pre-morbid symptoms¶ 238/ 769 (30.9) 1180/5937 (19.9) 750/3957 (19.0) <0.0001  5129/28800 (17.8) 3034/18109 (16.8) 
Management  
  Stroke unit 
  ICU  
 Withdrawal care 
 
680/763 (89.1) 
20/762 (2.6) 
21/764 (2.7) 
 
5856/5937 (98.6) 
112/5937 (1.9) 
105/5937 (1.8) 
 
3926/3957 (99.2) 
95/3957 (2.4) 
80/3957 (2.0) 
 
<0.0001 
0.71 
0.20 
  
28269/28800 (98.2) 
812/28800 (2.8) 
593/28800 (2.1) 
 
17962/18109 (99.2) 
731/ 18109 (4.0) 
434/18109 (2.4) 
Data are presented as n/N (%), mean (SD), median (IQR) 
ENCHANTED denotes the Enhanced Control of Hypertension and Thrombolysis Stroke study, ICU intensive care unit, mRS modified Rankin, 
NIHSS National Institutes of Health Stroke Scale, SSNAP Sentinel Stroke National Audit Programme, SU stroke unit. 
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*Defined from admission electrocardiogram and known diagnosis (history from primary or secondary health care record or from regular 
prescribed medication) in SSNAP. 
†Denominator of patients with fully completed NIHSS (not all patients had completed NIHSS at admission recorded in the SSNAP database) 
^This refers to aspirin (or other antiplatelet) or warfarin therapy on admission in atrial fibrillation patients only 
§P values refer to the comparison between ENCHANTED trial participants (column 2), and SSNAP eligible and treated patients (column 4) 
participating in ENCHANTED. 
¶Pre-morbid mRS of 1. 
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Table 2.  Death and disability in ENCHANTED trial participants compared to eligible and treated patients at ENCHANTED and all 
SSNAP sites in England and Wales* 
 ENCHANTED participants 
(n=770) 
SSNAP eligible and treated patients at ENCHANTED sites 
(n=3,957) 
P value 
Death or disability (mRS score 2-6) 411/719 (57.2) 2244/3736† (60.1) 0.15 
Death or disability (mRS score 3-6) 298/719 (41.5) 1660/3736† (44.4) 0.14 
Death 83/770 (10.8) 462/3957 (11.7) 0.48 
mRS score 
  0 
  1 
  2 
  3 
  4 
  5 
  6 
 
137 (19.1) 
171 (23.8) 
113 (15.7) 
106 (14.7) 
64 (8.9) 
45 (6.3) 
83 (11.5) 
 
723 (19.4) 
769 (20.6) 
584 (15.6) 
566 (15.1) 
535 (14.3) 
181 (4.8) 
378 (10.1) 
 
0.85 
0.054 
0.95 
0.78 
<0.0001 
0.11 
0.25 
Data are n/N (%) 
mRS denotes modified Rankin scale. 
*mRS data are at hospital separation and mortality data at 90 days for both datasets 
†Only available in SSNAP for records locked to discharge 
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Table 3.  Symptomatic intracerebral haemorrhage in ENCHANTED participants compared to eligible and treated patients at 
ENCHANTED and all SSNAP sites in England and Wales 
 ENCHANTED participants 
(n=770) 
SSNAP eligible and treated patients at ENCHANTED sites 
(n=3957) 
P value 
sICH 39/770 (5.1) 136/3957 (3.4) 0.028 
Death/neurological deterioration in 24 hours 53/770 (6.9) 462/3957 (11.7) <0.0001 
Data are n/N (%) 
sICH denotes symptomatic intracerebral haemorrhage, defined by National Institute of Health for Neurological Disorders and Stroke criteria. 
 
 
 
